En las noticias

Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial

Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.

I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer

The new issue of OncoDaily Magazine had the privilege to feature an exclusive interview with Dr. Benny Johnson, Senior Medical Director at Agenus, discussing his career and dedication to oncology, his motivation, professional vision for emerging treatments and personal experiences with cancer.

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer

Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting.

New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands

The combination of two drugs used to boost immune response could shrink tumours in 60 per cent of patients, according to the new research by Anglia Ruskin University.

Immunotherapies break into cold colorectal cancers at ASCO

Several immuno-oncology mechanisms on display at this year’s ASCO help the field inch closer to solving one of cancer immunotherapy’s biggest problems: achieving efficacy in cold solid tumors.

Agenus Inc.
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200